Who are Tnkase's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): low-dose tenecteplase intravenous thrombolysis, RiaSTAP, EVARREST™, Trypsin-Chymotrypsin, Tenecteplase thrombolysis, Traditional Cryoprecipitate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tenecteplase.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Tnkase — Competitive Intelligence Brief

Tnkase (TENECTEPLASE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed fibrin Immunology Enzyme Live · refreshed every 30 min

Target snapshot

Tnkase (TENECTEPLASE) — Roche. Tenecteplase binds to fibrin and converts plasminogen to plasmin, enhancing fibrin-specific plasmin generation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tnkase TARGET	TENECTEPLASE	Roche	marketed		fibrin	2000-01-01
low-dose tenecteplase intravenous thrombolysis	low-dose tenecteplase intravenous thrombolysis	Southwest Hospital, China	marketed	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin
RiaSTAP	RiaSTAP	Weill Medical College of Cornell University	marketed	Fibrinogen concentrate	Fibrinogen (Factor I)
EVARREST™	EVARREST™	Ethicon, Inc.	marketed	Topical hemostatic agent	Fibrinogen (Factor I) and thrombin (Factor IIa)
Trypsin-Chymotrypsin	Trypsin-Chymotrypsin	Dow University of Health Sciences	marketed	Proteolytic enzyme combination	Protein substrates and fibrin
Tenecteplase thrombolysis	Tenecteplase thrombolysis	Xuanwu Hospital, Beijing	marketed	Fibrinolytic agent / Thrombolytic	Fibrin; Plasminogen
Traditional Cryoprecipitate	Traditional Cryoprecipitate	Weill Medical College of Cornell University	marketed	Blood product; clotting factor concentrate	Fibrinogen, Factor VIII, von Willebrand factor, Fibronectin, Factor XIII

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tnkase — Competitive Intelligence Brief. https://druglandscape.com/ci/tenecteplase. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab